Rajasthan Plans End To India Policy Dependence For Open Market
This article was originally published in PharmAsia News
The head of Rajasthan Drugs and Pharmaceuticals says the company has benefited greatly by India's 2006 policy to cover 102 drugs made by central public-sector undertakings. Managing Director R.K. Vashishtha said Rajasthan's gain also was shared by other COSUs, which were given five years of automatic coverage by the government, public sector enterprises and non-government organizations. For Rajasthan, that has led to a large numbers of orders for its drugs, and the company now seeks to enter the open market with its products, eventually becoming self-reliant. (Click here for more
You may also be interested in...
While Novartis is continuing to provide hydroxychloroquine for ongoing investigator-initiated trials and support for study of a potential vaccine, it has decided to stop sponsoring hydroxychloroquine clinical trials. Meanwhile, Natco has announced donations of chloroquine phosphate for clinical trials, while Centrient and Beximco have provided PPE for healthcare workers.
New chief medical officers take up positions at Abeona Therapeutics, Akcea Therapeutics and Oncologie, while there are new CFOs at Affimed, NGM Biopharmaceuticals, Phathom Pharmaceuticals, Oncologie and Syndax Pharmaceuticals.
Consumers in the UK can now self-select a version of Infirst's lipid-driven ibuprofen Flarin brand.